A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients

BACKGROUND: Only a few prospective trials exist regarding the use of novel direct-acting antiviral agents (DAAs) in kidney transplant recipients (KTR) with chronic hepatitis C virus (HCV) infection. METHODS: This prospective single-center trial evaluated treatment with daclatasvir (DCV) and sofosbuv...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Nephrol
Autors principals: Duerr, Michael, Schrezenmeier, Eva V., Lehner, Lukas J., Bergfeld, Léon, Glander, Petra, Marticorena Garcia, Stephan R., Althoff, Christian E., Sack, Ingolf, Brakemeier, Susanne, Eckardt, Kai-Uwe, Budde, Klemens, Halleck, Fabian
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360788/
https://ncbi.nlm.nih.gov/pubmed/30717681
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-019-1218-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars